Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index. FIDELITY Post Hoc Analysis
Background Frailty is associated with a higher risk of adverse outcomes. It is believed that people with a higher frailty index (FI) may be less tolerant to new treatments, often leading to inappropriate prescribing. This post hoc analysis of FInerenone in chronic kiDney diseasE and type 2 diabetes:...
- Autores:
-
Rossing, Peter
Birkenfeld, Andreas L.
Fioretto, Paola
McGill, Janet B.
Anker, Stefan D.
Pitt, Bertram
Rohwedder, Katja
Scalise, Andrea
Scott, Charlie
Filippatos, Gerasimos
FIDELIO-DKD
FIGARO-DKD
- Tipo de recurso:
- Fecha de publicación:
- 2025
- Institución:
- Universidad Simón Bolívar
- Repositorio:
- Repositorio Digital USB
- Idioma:
- eng
- OAI Identifier:
- oai:bonga.unisimon.edu.co:20.500.12442/16670
- Acceso en línea:
- https://hdl.handle.net/20.500.12442/16670
https://doi.org/10.2215/CJN.0000000700
https://journals.lww.com/cjasn/fulltext/9900/finerenone_and_clinical_outcomes_in_ckd_and_type_2.611.aspx
- Palabra clave:
- CKD
Diabetes
- Rights
- openAccess
- License
- Attribution-NonCommercial-NoDerivatives 4.0 International